Press release content from Business Wire. The AP news staff was not involved in its creation.
Adalimumab: Sold Under the Brand Name Humira - Global Biosimilar Insight Report 2021 - ResearchAndMarkets.com
April 2, 2021 GMT
The “Adalimumab - Biosimilar Insight, 2021” report has been added to ResearchAndMarkets.com’s offering.
This “Adalimumab - Biosimilar Insight, 2021,” report provides comprehensive insights about 34+ companies and 35+ marketed and pipeline drugs in Adalimumab Biosimilars landscape.
ADVERTISEMENT
It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.